ArticleMolecular therapy. Oncology2025
Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- More tools to uncover cancer cells.Molecular therapy. Oncology · 2026Article
- Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Well-characterized tumor-associated antigens (TAAs) represent targets of interest in many anticancer therapeutic strategies. Although the use of monoclonal antibodies has led this field for years, the development of smaller molecules, with improved properties, holds great potential for specific anticancer applications. Affitins are small (7 kDa), thermostable, and high-affinity nonimmunoglobulin protein scaffolds derived from archaea. Using ribosome display and next-generation sequencing, we isolated the first Affitins specific for human mesothelin (hMSLN), a TAA overexpressed in many solid cancers and currently targeted in clinical trials. The homodimerization of the most promising Affitin (N13) improved affinity by 60-fold (from 35 nM to 0.57 nM). The high specificity of N13 was demonstrated on cell co-cultures under static or dynamic conditions. This Affitin, monomeric or dimeric, was also stable under a wide range of temperatures and upon repeated freeze/thaw cycles. Finally, bispecific natural killer (NK) cell engagers (BiKEs) composed of an anti-cluster of differentiation 16 (CD16) variable heavy domain of heavy chain (VHH) fused to a monomer or a dimer of N13 Affitins were constructed. Using a cytotoxicity assay, we showed the specific lysis of hMSLN-expressing cells in the presence of BiKE and NK cells, supporting the potential therapeutic application of these affinity agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.